- Population-based screening using prostate-specific antigen testing reduced prostate cancer mortality

Hoffman, Richard M.
December 2010
ACP Journal Club;12/21/2010, Vol. 153 Issue 6, p8
Academic Journal
The article reports on a study investigating whether population-based screening using prostate-specific antigen (PSA) testing is helpful in reducing prostate cancer mortality. As reported, 20 000 randomly selected men of 50 to 64 years of age participated in this study. The study found that prostate cancer mortality was reduced by population-based screening using PSA testing but it increased detection of prostate cancer.


Related Articles

  • Prostate cancer screening: a survey of attitudes and practices among Finnish physicians in 1999 and 2007. Pogodin-Hannolainen, Dimitri; Juusela, Harri; Tammela, Teuvo L. J.; Ruutu, Mirja; Aro, Jussi; Määttänen, Liisa; Auvinen, Anssi // Journal of Medical Screening;Mar2011, Vol. 18 Issue 1, p46 

    Objective To evaluate the attitudes and practices related to prostate-specific antigen (PSA) screening for prostate cancer (PC) among Finnish physicians in 1999 and 2007. Materials and methods The first questionnaire survey was conducted in 1999 with a mailing to 102 urologists, 679 community...

  • New queries about PSA screenings.  // Consumer Reports on Health;Jun2011, Vol. 23 Issue 6, p3 

    The article reports on research which was published online by the "Journal of the National Cancer Institute" and found that measuring the rate at which a man’s level of prostate-specific antigen (PSA) rises is no better than the standard PSA test at predicting prostate cancer.

  • 2012 - Periodic PSA-based screening in men 55 to 69 years of age reduced prostate cancer mortality. Hoffman, Richard M. // ACP Journal Club;7/17/2012, Vol. 157 Issue 2, p1 

    The article reports regular screening of prostate specific antigen (PSA) in blood serum of men between 55 to 69 years helps in early detection of prostate cancer. It mentions that cancer mortality is reduced only to a certain level by regular screening of PSA but with long term follow up of...

  • 2011 - Review: PSA-based screening does not reduce prostate cancer mortality or all-cause mortality. Dahm, Philipp // ACP Journal Club;4/17/2012, Vol. 156 Issue 4, p1 

    The article focuses on a study conducted to analyze the effectiveness of PSA-based screening for the treatment of prostate cancer. It mentions that this methodology is effective due to its capability of risk assessment. It is also informed that this screening will be helpful for young people and...

  • Abstract 18 -- PSA Screenings for Prostate Cancer: Current Status, Future Directions. Godley, Paul A. // Oncologist;Oct2012 Supplement, Vol. 17 Issue S2, p8 

    The article presents an abstract on the current status of prostate specific antigen (PSA) testing for prostate cancer.

  • Clinical digest. Initial test identifies men who will benefit from prostate cancer screening.  // Nursing Standard;4/23/2014, Vol. 28 Issue 34, p17 

    The article discusses research in the article "Influence of Blood Prostate Specific Antigen Levels at Age 60 on Benefits and Harms of Prostate Cancer Screening: Population Based Cohort Study" by S. Carlsson et al., which appeared in a 2014 issue of the "British Medical Journal" and found a test...

  • Mortality reductions produced by sustained prostate cancer screening have been underestimated. Hanley, James A. // Journal of Medical Screening;Sep2010, Vol. 17 Issue 3, p147 

    Background The recently published European Randomized Study of Screening for Prostate Cancer (ERSPC) reported prostate specific antigen (PSA)-based screening to have reduced the prostate cancer death rate by only 20%. However, this is an underestimate caused by (i) including in the 20% the years...

  • To Screen or Not to Screen: Ongoing Debate in the Early Detection of Prostate Cancer. Marroquin, Joanna Marie // Clinical Journal of Oncology Nursing;Feb2011, Vol. 15 Issue 1, p97 

    Debate about the use of prostate-specific antigen (PSA) tests to screen prostate cancer in men is ongoing. Prostate cancer is the most common cancer after skin cancer in men and the second most deadly after lung cancer. An elevated PSA level can lead to this cancer's diagnosis and treatment even...

  • Influence of blood prostate specific antigen levels at age 60 on the benefits and harms of prostate cancer screening: population based cohort study. Carlsson, Sigrid; Assel, Melissa; Sjoberg, Daniel; Ulmert, David; Hugosson, Jonas; Lilja, Hans; Vickers, Andrew // BMJ: British Medical Journal;4/26/2014, Vol. 348 Issue 7955, p11 

    The article presents a study on the effect of blood prostate specific antigen levels at the age of 60 on the benefits and dangers of medical screening for prostate cancer. It discusses the participants and the method used in the study, the rate ratio for death from prostate cancer by screening,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics